Glucagon Like Peptide-1 (GLP-1) Agonists Market 2021 Analysis by Top Manufacturers| Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi, Bristol-Myers Squibb, Amylin

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Insights and Forecast to 2027

Glucagon Like Peptide-1 (GLP-1) Agonists Market research performs thorough market analysis and uses a variety of sources to provide key players with wide-ranging knowledge about industry strategies. This analysis concentrates more on current trends, market scenario along with depicting dynamic methods and key advancements. All these factors greatly help leading industries to get an advantage over competitive market and leverage their position in the market. Key players of the market focus on following some key strategies such as mergers, acquisitions, collaborations and novel product launches. It further captures actions and plans followed by the competitors in the market to make their business gainful. Glucagon Like Peptide-1 (GLP-1) Agonists Market study discusses about how COVID-19 pandemic affected market growth globally.

The Global Glucagon Like Peptide-1 (GLP-1) Agonists market is expected to register a CAGR of 26.34 % during the forecast period (2021- 2027).

The report introduces the market competition landscape and a detailed analysis of the major suppliers/key players in the market.

Top companies in the global Glucagon Like Peptide-1 (GLP-1) Agonists market: Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi, Bristol-Myers Squibb, Amylin

INDUSTRY NEWS

AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.

AstraZeneca now has an enhanced scientific presence in immunology and, through Alexion’s innovative complement-biology platform and robust pipeline, will continue to pioneer the discovery and development of medicines for patients with rare diseases. Rare diseases represent a significant unmet medical need and becomes a high-growth opportunity for the Company.

Click on the link to get a free sample copy of the report:

https://www.marketintelligencedata.com/reports/567774/global-glucagon-like-peptide-1-glp-1-agonists-market-insights-and-forecast-to-2027/inquiry?Mode=Radhika

Market Overview

The glucagon-like peptide-1 (GLP-1) agonists market is expected to see a considerable amount of growth during the forecast period. The increase is mainly attributed to the improved efficiency of GLP-1. 
Increasing diabetes prevalence in established and emerging countries is expected to drive the market. The increase in the diabetic population over the years is due to the overall effect of individual-level factors, like the increasing median age of the population and health factors, including increasing rates of obesity and inactivity levels among people. 

The global Glucagon Like Peptide-1 (GLP-1) Agonists market is divided by product type and application:

The report breaks down the global Glucagon Like Peptide-1 (GLP-1) Agonists market according to the following types:

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

According to the application, the global Glucagon Like Peptide-1 (GLP-1) Agonists market can be subdivided into:

Hospital

Pharmacy

Other

Regional Outlook of the Glucagon Like Peptide-1 (GLP-1) Agonists market:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia and Italy)

Asia Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

Middle East and Africa (Saudi Arabia, UAE) , Egypt, Nigeria and South Africa)

North America to Dominate the Market in Terms of Revenue

North America accounts for 77% of the overall GLP-1 market and is expected to witness a growth rate of 6.53%, during the forecast period.
In the Middle East & Africa, the GLP-1 market is expected to see high growth during the forecast period, with a CAGR of 25.08%.
In Asia-Pacific, according to the International Diabetes Federation, Japan and Australia have the highest per capita expenditure, of upwards of USD 3,000. However, China and India have the highest diabetes prevalence.

Buy Now Link

https://www.marketintelligencedata.com/report/purchase/567774?mode=su?Mode=Radhika

The Influence of the Glucagon Like Peptide-1 (GLP-1) Agonists market report:

-Comprehensive assessment of all opportunities and risks in the Glucagon Like Peptide-1 (GLP-1) Agonists market.

-The latest innovations and major events in the Glucagon Like Peptide-1 (GLP-1) Agonists market.

-Research in detail the business strategy of leading enterprises in the Glucagon Like Peptide-1 (GLP-1) Agonists market.

-Conclusive research on the growth chart of the Glucagon Like Peptide-1 (GLP-1) Agonists market in the next few years.

-In-depth understanding of the Glucagon Like Peptide-1 (GLP-1) Agonists market, especially the driving factors, constraints and major micro-markets.

-Have a good impression on the important technologies of the Glucagon Like Peptide-1 (GLP-1) Agonists market and the latest market trends.

Browse the report description and table of contents:

https://www.marketintelligencedata.com/reports/567774/global-glucagon-like-peptide-1-glp-1-agonists-market-insights-and-forecast-to-2027?Mode=Radhika

Key Highlights of the Glucagon Like Peptide-1 (GLP-1) Agonists Market Report

Market Segments and other perspectives have been studied across 3600 perspectives
Both Supply and Demand-side mapping has been done to understand the market scenario
We have used data triangulation to derive the market numbers
Our data and analysis have been verified through C-level Executives while conducting primary interviews
Porter’s Five Forces Analysis, Swot, Analysis, PEST Analysis, Value Chain Analysis and Market Attractiveness would be an added advantage in the report
Historical Year: 2016; Base Year: 2021; Forecast Years: 2021 – 2027

We will get in touch with you within 24hrs and help you find the research reports and Additional Customization you need.

About Us:

Market intelligence data is a global front-runner in the research industry, offering contextual and data-driven research services to customers. Customers are supported in creating business plans and attaining long-term success in their respective marketplaces by the organization. The industry provides consulting services, Market Intelligence Data research studies, and customized research reports.

Contact Us:

Irfan Tamboli (Head of Sales) – MARKET INTELLIGENCE DATA

Phone: +1 (704) 266-3234

Mail to: sales@marketintelligencedata.com

This release was published on openPR.